DUBLIN--(BUSINESS WIRE)--The "Neuroblastoma - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
The market of Neuroblastoma in 7MM was found to be USD 733.58 million in 2016, and is expected to increase at from 2016-2027.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Neuroblastoma in the United States, EU5, and Japan.
One segment of Neuroblastoma report encloses the detailed analysis of marketed drugs and late stage pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Detailed chapter for upcoming therapies Naxitamab, Omburtamab, Bevacizumab, Irinotecan and Temozolomide, CPP-1X, MNX-100 etc., have been covered in the report.
The Neuroblastoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
Another segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
- Y-mAbs Therapeutics Inc.
- United Therapeutics Corp.
- Genentech, Inc.
- EUSA Pharma
- Cancer Prevention Pharmaceuticals
Key Topics Covered:
1. Key Insights
2. Neuroblastoma Market Overview At A Glance
3. Market Share (%) Distribution Of Neuroblastoma In 2017
4. Market Share (%) Distribution Of Neuroblastoma In 2027
5. Disease Background And Overview
7. Epidemiology And Patient Population
8. Key Findings
9. Population And Forecast Parameters
10. 7Mm Total Incident Patient Population Of Neuroblastoma
11. Country Wise-Epidemiology Of Neuroblastoma
12. Current Treatment And Medical Practices
13. Marketed Drugs
14. Key-Cross Competition
15. Pipeline Profiles
16. Neuroblastoma: Market Analysis
17. Market Drivers
18. Market Barriers
20. Report Methodology
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/36x2zx/neuroblastoma?w=4